Skip to main content
. 2019 Nov 12;11(11):600. doi: 10.3390/pharmaceutics11110600

Figure 5.

Figure 5

Therapy studies in PC3 tumor bearing mice using P5Y/siRNA (A) or P10Y/siRNA (B) complexes targeting either the oncogenes PLK1 or survivin. Mice were intraperitoneally treated with the complexes equivalent to 10 µg siRNA every 2–3 days. Tumor growth curves (upper panels) demonstrate the growth inhibiting effects of the specifically treated groups as compared to a negative control treated or untreated group. Lower panels: representative examples of mice.